Clinical Trial Update: Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of zanubrutinib and rituximab for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING